1. Senkus, E, Kyriakides, S, Ohno, S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26(Suppl. 5): v8–v30.
Google Scholar | Crossref | Medline | ISI2. Nitz, U, Gluz, O, Huober, J, et al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2014; 25: 1551–1557.
Google Scholar | Crossref | Medline3. Gnant, M, Filipits, M, Greil, R, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence Score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014; 25: 339–345.
Google Scholar | Crossref | Medline | ISI4. Voogd, AC, Nielsen, M, Peterse, JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001; 19: 1688–1697.
Google Scholar | Crossref | Medline | ISI5. Mirza, AN, Mirza, NQ, Vlastos, G, et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10–26.
Google Scholar | Crossref | Medline | ISI6. de Bock, GH, Putter, H, Bonnema, J, et al. The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. Breast Cancer Res Treat 2009; 117: 401–408.
Google Scholar | Crossref | Medline7. Ades, F, Zardavas, D, Bozovic-Spasojevic, I, et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol 2014; 32: 2794–2803.
Google Scholar | Crossref | Medline8. Wishart, GC, Azzato, EM, Greenberg, DC, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Canc Res 2010; 12: R1.
Google Scholar | Crossref | Medline | ISI9. Wishart, GC, Bajdik, CD, Dicks, E, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Canc 2012; 107: 800–807.
Google Scholar | Crossref | Medline | ISI10. Wishart, GC, Bajdik, CD, Azzato, EM, et al. A population-based validation of the prognostic model PREDICT for early breast cancer. Eur J Surg Oncol 2011; 37: 411–417.
Google Scholar | Crossref | Medline11. Jackisch, C, Harbeck, N, Huober, J, et al. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care Basel Switz 2015; 10: 211–219.
Google Scholar | Crossref | Medline12. Filipits, M, Rudas, M, Jakesz, R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17: 6012–6020.
Google Scholar | Crossref | Medline13. Sestak, I, Martín, M, Dubsky, P, et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Canc Res Treat 2019; 176: 377–386.
Google Scholar | Crossref | Medline14. Harris, LN, Ismaila, N, McShane, LM, et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract 2016; 12: 384–389.
Google Scholar | Crossref | Medline | ISI15. Prise en charge | EndoPredict International . https://endopredict.eu/ (accessed 22 February 2019).
Google Scholar16. Cardoso, F, Kyriakides, S, Ohno, S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1194–1220.
Google Scholar | Crossref | Medline17. Müller, BM, Keil, E, Lehmann, A, et al. The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions. PloS One 2013; 8: e68252.
Google Scholar | Crossref | Medline18. Ettl, J, Klein, E, Hapfelmeier, A, et al. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1. PloS One 2017; 12: e0183917.
Google Scholar | Crossref | Medline19. Villarreal-Garza, C, Deneken-Hernandez, Z, Maffuz-Aziz, A, et al. Abstract P2-08-54: Change in therapeutic management after EndoPredict assay in a prospective decision impact study of Mexican premenopausal patients. Cancer Res 2019; 79: P2-08-54-P2-08–54.
Google Scholar20. Penault-Llorca, F, Kwiatkowski, F, Arnaud, A, et al. Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14). Breast Edinb Scotl 2019; 49: 132–140.
Google Scholar | Crossref | Medline21. Curigliano, G, Burstein, HJ, Winer, EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28: 1700–1712.
Google Scholar | Crossref | Medline22. Lo, SS, Mumby, PB, Norton, J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010; 28: 1671–1676.
Google Scholar | Crossref | Medline | ISI23. Albanell, J, González, A, Ruiz-Borrego, M, et al. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann Oncol 2012; 23: 625–631.
Google Scholar | Crossref | Medline24. Nicolaï, V, Longué, M, Duprez-Paumi, R, et al. Les journées passées de la SFSPM de 2009 à 2017 : Société Française de Sénologie et de Pathologie Mammaire. http://sfspm.org/journeespassees-detail-posters-267 (accessed 8 March 2019).
Google Scholar25. Bonastre, J. L’accès aux soins en cancérologie :évolution de l’offre et recours aux soins entre 2005 et 2012. 2005; 8: 5–7.
Google Scholar26. Haute Autorité de Santé - Utilité clinique des signatures génomiques dans le cancer du sein de stade précoce - Rapport d’évaluation . https://webzine.has-sante.fr/portail/jcms/c_2748998/en/clinical-utility-of-genomic-signatures-in-early-stage-breast-cancer-inahta-brief#_ftn1 (accessed 18 May 2019).
Google Scholar27. Fekih, M, Petit, T, Zarca, D, et al. Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey. Bull Cancer (Paris) 2014; 101: 918–924.
Google Scholar | Crossref | Medline28. Gradishar, WJ, Anderson, BO, Balassanian, R, et al. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw 2017; 15: 433–451.
Google Scholar | Crossref | Medline29. Cardoso, F, van’t Veer, LJ, Bogaerts, J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016; 375: 717–729.
Google Scholar | Crossref | Medline30. Goldhirsch, A, Wood, WC, Gelber, RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133–1144.
Google Scholar | Crossref | Medline | ISI